347 related articles for article (PubMed ID: 3080526)
1. The antimetastatic function of concomitant antitumor immunity. II. Evidence that the generation of Ly-1+2+ effector T cells temporarily causes the destruction of already disseminated tumor cells.
Dye ES
J Immunol; 1986 Feb; 136(4):1510-5. PubMed ID: 3080526
[TBL] [Abstract][Full Text] [Related]
2. The antimetastatic function of concomitant antitumor immunity. I. Host Ly-1+2+ effector T cells prevent the enumeration of metastatic tumor cells in a biological assay.
Dye SE
J Immunol; 1986 Feb; 136(4):1504-9. PubMed ID: 3080525
[TBL] [Abstract][Full Text] [Related]
3. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
Yoshizawa H; Chang AE; Shu S
J Immunol; 1991 Jul; 147(2):729-37. PubMed ID: 1830072
[TBL] [Abstract][Full Text] [Related]
4. Expression of passively transferred immunity against an established tumor depends on generation of cytolytic T cells in recipient. Inhibition by suppressor T cells.
Mills CD; North RJ
J Exp Med; 1983 May; 157(5):1448-60. PubMed ID: 6189937
[TBL] [Abstract][Full Text] [Related]
5. In vivo and in vitro antitumor activity expressed by cells of concomitantly immune mice.
Tuttle RL; Knick VC; Stopford CR; Wolberg G
Cancer Res; 1983 Jun; 43(6):2600-5. PubMed ID: 6133611
[TBL] [Abstract][Full Text] [Related]
6. Specific and nonspecific antitumor immunity. III. Specific T lymphocyte-mediated cytolysis of P815 mastocytoma and SL2 lymphoma by draining lymph node cells from syngeneic tumor-bearing DBA/2J mice.
Germain RN; Williams RM; Benacerraf B
Am J Pathol; 1976 Dec; 85(3):661-74. PubMed ID: 826167
[TBL] [Abstract][Full Text] [Related]
7. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells.
Shu S; Krinock RA; Matsumura T; Sussman JJ; Fox BA; Chang AE; Terman DS
J Immunol; 1994 Feb; 152(3):1277-88. PubMed ID: 8301131
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice.
Fuyama S; Yamamoto H; Fujii Y; Arai S
Cancer Res; 1986 Nov; 46(11):5548-52. PubMed ID: 2428480
[TBL] [Abstract][Full Text] [Related]
9. Tumor-specific suppressor T-cells which inhibit the in vitro generation of cytolytic T-cells from immune and early tumor-bearing host spleens.
Bear HD
Cancer Res; 1986 Apr; 46(4 Pt 1):1805-12. PubMed ID: 2936451
[TBL] [Abstract][Full Text] [Related]
10. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy.
Shu SY; Chou T; Rosenberg SA
J Immunol; 1987 Jul; 139(1):295-304. PubMed ID: 2953816
[TBL] [Abstract][Full Text] [Related]
11. In vivo activity of lymphokine-activated macrophages in host defense against neoplasia.
Fernandez-Cruz E; Ulich T; Schreiber RD
J Immunol; 1985 May; 134(5):3489-96. PubMed ID: 3920323
[TBL] [Abstract][Full Text] [Related]
12. Phenotype analyses and cellular mechanisms of the pre-effector T-lymphocyte response to a progressive syngeneic murine sarcoma.
Sakai K; Chang AE; Shu SY
Cancer Res; 1990 Jul; 50(14):4371-6. PubMed ID: 2114215
[TBL] [Abstract][Full Text] [Related]
13. Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells.
Shu S; Rosenberg SA
J Immunol; 1985 Oct; 135(4):2895-903. PubMed ID: 2411817
[TBL] [Abstract][Full Text] [Related]
14. Intracamerally induced concomitant immunity: mice harboring progressively growing intraocular tumors are immune to spontaneous metastases and secondary tumor challenge.
Niederkorn JY; Streilein JW
J Immunol; 1983 Nov; 131(5):2587-94. PubMed ID: 6415174
[TBL] [Abstract][Full Text] [Related]
15. B7-negative versus B7-positive P815 tumor: differential requirements for priming of an antitumor immune response in lymph nodes.
Yang G; Mizuno MT; Hellström KE; Chen L
J Immunol; 1997 Jan; 158(2):851-8. PubMed ID: 8993003
[TBL] [Abstract][Full Text] [Related]
16. Studies on the minimum requirements for in vitro "cure" of tumor cells by cytotoxic T lymphocytes.
Miki S; Ksander B; Streilein JW
Reg Immunol; 1992; 4(6):352-62. PubMed ID: 1297406
[TBL] [Abstract][Full Text] [Related]
17. Hybrid resistance to BALB/c plasmacytomas: F1 hybrid anti-MPC-11 immunological responses correlated with resistance to tumor challenge.
Marsili MA; Walker MC; Phillips-Quagliata JM
Cancer Res; 1986 Jan; 46(1):190-7. PubMed ID: 3484380
[TBL] [Abstract][Full Text] [Related]
18. Anti-estrogens potentiate the immunotherapy of the P815 murine mastocytoma by cytotoxic T lymphocytes.
Nagy E; Baral E; Kangas L; Berczi I
Anticancer Res; 1997; 17(2A):1083-8. PubMed ID: 9137453
[TBL] [Abstract][Full Text] [Related]
19. Importance of B7-1-expressing host antigen-presenting cells for the eradication of B7-2 transfected P815 tumor cells.
La Motte RN; Sharpe AH; Bluestone JA; Mokyr MB
J Immunol; 1998 Dec; 161(12):6552-8. PubMed ID: 9862681
[TBL] [Abstract][Full Text] [Related]
20. Degradation of specificity in cytolytic T lymphocyte clones. The separate YAC-1-type (NK-like) and P815-type broad specificity killing patterns are both restricted to the larger cells within a clone but may be expressed independently in clones from different mouse strains.
Shortman K; Wilson A
J Immunol; 1986 Aug; 137(3):798-804. PubMed ID: 2424983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]